Research

Texas D-CFAR Grants and Funding

Master
Content

We provide our members with support to do cutting-edge research through:

  • Introductions to collaborators from our home institutions and the wider network of HIV leading investigators
  • Identifying opportunities for funding through NIH or other funding bodies
  • Providing strategies for competitive grant applications and feedback from senior investigators on grant drafts  
  • Assistance with organizing multi-investigator grant submissions

For funding opportunities visit the following sites:

Notice of Extension of NOT-HL-20-761 "Notice of Special Interest (NOSI): Pulmonary Complications of Hematopoietic Stem Cell Transplantation in Childhood". Expires Jan. 1, 2025

Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed). Expires July 2, 2024

Notice of Special Interest (NOSI): Administrative Supplements for Research on Womens Health in the IDeA States. Expires Oct. 18, 2024

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required). Expires July 2, 2024

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed). Expires July 2, 2024

Notice of Expiration of NOT-HL-19-677 "Notice of Special Interest SEARCH: Stimulating ExplorAtory Research on HIV/AIDS Contribution to Heart, Lung, Blood and Sleep Comorbidities (R01 - Clinical Trial Not Allowed)". Expires Jan. 1, 2025

Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed). Expires July 2, 2024

Application Due Date Changes for RFA-HL-23-013, "Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)". Expires Jan. 1, 2025

Application Due Date Changes for RFA-HL-23-014, "Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33)". Expires Jan. 1, 2025

Notice of Application Due Date Changes for RFA-HL-23-011,"Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)". Expires Jan. 1, 2025

NIMH FOAs

NOT-MH-20-013: Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment

NOT-MH-20-019: Notice of Special Interest (NOSI): Strengthening the HIV Prevention Continuum

NOT-MH-20-020: Notice of Special Interest: Stigma or Other Social Determinants of Health (SDOH) in HIV Prevention and Treatment

NOT-MH-20-023: Notice of Special Interest (NOSI): Strengthening the HIV Care Continuum

NOT-MH-20-024: Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets

NOT-MH-20-035: Notice of Special Interest (NOSI): Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults

NOT-MH-21-105: Notice of Special Interest (NOSI): Advancing Health Communication Research on HIV Prevention, Treatment, and Cure

NOT-MH-22-095: Notice of Special Interest (NOSI): NIMH Priorities on Research on Aggression and Violence Against Others

PA-20-144: Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

PA-20-141: Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)

PA-20-145: Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

PAR-20-307: Developmental AIDS Research Centers on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

PAR-21-228: NIMH Research Education Mentoring Program for HIV/AIDS Researchers (R25 Clinical Trial Not Allowed)

PAR-20-308: AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

PAR-20-151: Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)

PAR-20-149: HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed)

RFA-MH-22-170: Advancing communication strategies to support future HIV vaccine use (R01 Clinical Trial Optional)

RFA-MH-22-171: Advancing communication strategies to support future HIV vaccine use (R21 Clinical Trial Optional)

Co-Sponsored FOAs

NOT-AI-21-054: Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV

NOT-AI-21-057: Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide

NOT-CA-22-037: Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research

NOT-OD-22-069: Notice of Special Interest (NOSI): Support for existing data repositories to align with FAIR and TRUST principles and evaluate usage, utility, and impact

NOT-OD-22-065: Notice of Special Interest (NOSI): Administrative Supplements for Advancing the Ethical Development and Use of AI/ML in Biomedical and Behavioral Sciences

NOT-OD-22-067: Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data

NOT-OD-22-068: Notice of Special Interest (NOSI): Administrative Supplements to Support Enhancement of Software Tools for Open Science

NOT-DA-21-060: Notice of Special Interest (NOSI): Reducing Stigma Related to Drug Use in Human Service Settings

NOT-OD-21-100: Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health

NOT-MD-22-006: Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

NOT-AI-21-011: Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research

NOT-CA-22-037: Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research

NOT-MH-22-095: Notice of Special Interest: NIMH Priorities on Aggression and Violence Against Others

PAR-21-303: Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)

PAR-21-068: Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

PAR-20-036: Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) 

PAR-21-344: Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional)

PAR-21-297: Novel Systemic Options for Young Adults under the tab PA-Joint; Multipurpose Prevention Technology 

PAR-21-070: Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)

PAR-21-297: Multipurpose Prevention Technology: Novel Systemic Options for Young Adults